26. REASONABLENESS OF DEVELOPING A NEW ANTIFUNGAL PRODUCT IN THE FORM OF EAR DROPS ANTINEOPLASTIC AGENTS, AVAILABLE ON PHARMACEUTICAL MARKET OF THE REPUBLIC OF MOLDOVA

Voloşin Anastasia, Suvorchina Olga

Scientific adviser: Uncu Livia, Ph.D., Associate professor, Department of Pharmaceutical and Toxicological chemistry, State Medical and Pharmaceutical University "Nicolae Testemitanu", Chişinău, Republic of Moldova

Introduction: There has been an increase in the prevalence of otomycosis in recent years. The most recommended and dominate treatment of otomycosis, is topical instillation of ear drops. Ear drops provide the advantages of combination therapy, extending the range of therapeutic options. Considering poly-etiology of this disease (the possible presence of fungal bacterial flora), treatment should include antimicrobial, antifungal, antiinflammatory, and if necessary, an analgesic effect that is achieved by the use of combined ear drops.

Purpose and objectives: analyze the available pharmaceutical products used for treatment of otomycosis. The rational application of these medications makes it possible to eliminate rapidly a variety of etiological factors, reduce the severity of inflammation, and to improve the quality of patient's life.

Materials and methods: Forresearch it was used State Nomenclature of drugs of Republic of Moldova (01.03.2014); Nomenclature of drugs of Romania (01.03.2014); State Register of drugs of Russia (01.03.2014); Formulation of European Medical Agency (01.03.2014); Formulation of USA (FDA Drugs) (20.02.2014); Great Britain Formulation (01.02.2014); instructions for use of drugs; Standards of quality of analytical documents and therapeutic protocols in otorhinolaryngology (section "ear diseases").

Results:Combined eardrops were analyzed in terms of their presence in the pharmaceutical market of RM in comparing with Russia, EU countries, USA and Canada. Nomenclatures of drugs from 7 countries (Moldova, Romania, Russia, Britain, France, USA and Canada) were examined. The results indicate that most frequently used 43 names of combined ear drops produced by 38 companies from 15 countries. Of these 38 companies only 2 produce combined ear drops which contains antifungal component. The pharmaceutical market in RM has 13 names of ear drops. The most products (58.3%) are combinations of antimicrobial v, corticosteroids, anti inflammatory, anesthetic and antiseptic medicines. Unfortunately, there are notregistered combined ear drops that contain antifungal component.

Conclusions: In conclusion it is important to develop a new composition of ear drops, containing antibacterial and antifungal components.

Keywords: otomycosis, combined ear drops, antifungal medicines.

27. CONTEMPORARY PRINCIPLES OF PHARMACOTHERAPY URTICARIA Ciubara Olesea

Academic adviser. Scutari Corina, M.D., Ph.D., Associate professor, State Medical and Pharmaceutical University "Nicolae Testemitanu", Republic of Moldova

Introduction: Chronic urticaria represents 25% of cases of urticaria, and is twice as common in women, especially in people between the ages of 25 and 50 years. Resulting from incidence of this disease in Republic of Moldova, it is required to effectuate a clinical study with the elucidation of the etiology, symptomatology and pharmacotherapy of patients with urticaria.

Materials and methods: The trial was conducted at Republican Clinical Hospital I.M.P.S, Department of Allergology. Working methodology consisted in the creation and registration of 97 cases of urticaria and angioedema hospitalizations in 2013 year in Allergology Departament.

Results and discussions: In the Department of Allergology, 97 patients were admitted with the diagnosis of urticaria and angioedema, including 53 women and 44 men. Regarding the employment status, 68 patients were employed in different sectors, three students of 12th class, 6 don't work, and 10 were retired by age and had the degree of disability. It is found that in 37.1% of cases, patients are